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Sepsis is a common condition, and more than 19 million cases of severe sepsis (i.e. 
cases where organ dysfunction has occurred as a result of sepsis) occur each year1.  
Despite many decades of research, the mortality rate remains approximately 30%, 
and survivors are often left with a significant morbidity burden, including 
neurocognitive impairment, neuromuscular weakness and persistent organ 
dysfunction2. End-organ dysfunction and injury ensues in part as a result of innate 
immune cells (including neutrophils) failing to control pathogen invasion, which leads 
to microbial proliferation, release of inflammatory mediators, endothelial dysfunction, 
and tissue injury.  On page xxx of this issue, Ruchaud-Sparagano and colleagues 
present novel data investigating the hypothesis that monophosphoryl lipid A (MPLA), 
a derivative of lipopolysaccharide (LPS), can ameliorate the release of cytotoxic 
mediators from neutrophils without impairing bacterial clearance3.  Maintenance of 
efficient neutrophil phagocytic and bactericidal function in the absence of significant 
release of cytotoxic mediators would be an attractive therapeutic strategy for septic 
patients. 
 
Using clinically relevant in vitro models, the authors show that exposing neutrophils 
to MPLA, in contrast to LPS, does not result in the release of reactive oxygen 
species and myeloperoxidase.  In contrast to LPS, pre-exposure of MPLA treated 
neutrophils to a blocking antibody for TLR4 augemented myeloperoxidase release, 
suggesting that LPS and MPLA differentially modulates TLR4.   Despite ameliorated 
production of superoxide and myeloperoxidase, MPLA exposed neutrophils retained 
P.aeruginosa killing abilities, implying that bacterial killing may not be related to the 
amount of enzymes released by neutrophils, and intriguingly that superoxide 
independent killing mechanisms may exist, at least in MPLA exposed neutrophils.  
Ruchaud-Sparagano and colleagues also observed no difference in the release of 
TNFα, IL-1β and IL-10 from MPLA and LPS treated neutrophils.  However, there was 
a significant reduction in the release of the potent neutrophil chemoattractant IL-8 
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from MPLA treated cells, mediated via the PI3kinase pathway.   LPS exposure was 
also found to increase neutrophil cell surface TLR4 expression, a phenomenon that 
did not occur with MPLA.  The contrasting effects of MPLA and LPS are summarized 
in Table One 
 
The observations that administration of MPLA after LPS exposure reduced 
superoxide and myeloperoxidase release, and that MPLA abrogated increased TLR4 
cell surface expression in LPS treated neutrophils whilst preserving efficient bacterial 
killing, support the notion that MPLA may hold promise as adjunctive therapy for 
Gram negative sepsis.  Persistent activation of TLR pathways, as occurs in the early 
stages of sepsis, has been associated with excessive release of inflammatory 
cytokines and the development of tissue injury in sepsis4,5. In contrast to the current 
paper, a study of 20 patients treated with a synthetic lipid A analogue prior to 
intravenous endotoxin, demonstrated decreased serum concentrations of the pro-
inflammatory cytokines TNFα, IL-1β, IL-8 and IL-6, in the presence of increased 
circulating neutrophil numbers.  It would seem reasonable to speculate that reduced 
IL-8 release, coupled with preserved chemotaxis in MPLA treated cells, to other 
chemoattractants such as LTB4, may serve to optimize neutrophil recruitment to sites 
of pathogen invasion without the sequellae of exuberant, mediator-induced tissue 
injury.  
 
The current work also seeks to determine the mechanistic basis of the contrasting 
responses of neutrophils to LPS and MPLA, demonstrating the differential signaling 
responses of LPS and MPLA downstream of TLR4.  TLR4 activation can lead to 
activation of the MyD88 and TRIF pathways.  IL-8 production requires recruitment of 
MyD88 to TLR4; based on the ameliorated concentrations of IL-8 produced by MPLA 
exposed neutrophils, it is plausible that the differential TLR4 effects of LPS and 
MPLA may be mediated via differential activation of pathways downstream of TLR4.  
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LPS, but not MPLA, triggered IκB kinase (IKK) phosphorylation, which results from 
MyD88 activation, whereas both LPS and MPLA induced interferon regulatory factor 
3 (IRF3) activation, which is downstream of TRIF. Both LPS and MPLA were able to 
trigger p38 MAPK phosphorylation (an event downstream from both MyD88 and 
TRIF), and LPS, but not MPLA induced JNK phosphorylation, which occurs 
downstream from MyD88, and to a less extent TRIF. Thus this differential activation 
of MyD88 and TRIF likely explains the different effects of LPS and MPLA on TLR4 
up-regulation. 
Sepsis is a heterogeneous and poorly defined clinical syndrome. The continued 
absence of sepsis therapies suggests that our knowledge of the underlying biology of 
sepsis remains limited, and a paucity of mechanistic and preclinical data to support 
the interventions trialled, continues to hamper the rational development of 
therapeutic interventions for sepsis (e.g.7,8,9). Attempts to target (and antagonise) 
single molecules implicated in sepsis have proved futile in clinical trials, reinforcing 
the notion that therapies that modulate the body’s innate immune response, such as 
MPLA, may be more likely to demonstrate clinical benefit as adjuncts to standard 
therapy (antibiotics). We should therefore welcome preclinical human data such as 
these that inform the field of neutrophil biology and may lead to the development of 
new therapies for this widespread and often devastating condition. 
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Table one – effects of LPS and MPLA on human neutrophils 
 LPS MPLA 
Superoxide anion generation Increased Not increased 
Myeloperoxidase release Increased Not increased 
Phagocytosis Increased Trending towards 
increased 
Gram negative bacterial killing Preserved Preserved 
Acidification of phagolysosomes Preserved Preserved 
IL-8 release Increased Not increased 
TLR4 cell surface expression Increased Not increased 
Chemotaxis towards fMLP Decreased Not decreased 
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